Direct differentiation method for making cardiomyocytes from human embryonic stem cells

• US 7,897,389 B2
• Filed: 09/15/2008
• Issued: 03/01/2011
• Est. Priority Date: 03/26/2004
• Status: Active Grant

• Current Assignee: Asterias Biotherapeutics Incorporated (Lineage Cell Therapeutics, Inc.)
• Original Assignee: Geron Corporation
• Inventors: Gold, Joseph D., Collins, Lila R., Hassanipour, Mohammad, Xu, Chunhui
• Primary Examiner(s): Ton; Thaian N
• Application Number:
  US12/210,779
• Publication Number:
  US 20090047739A1
• Time in Patent Office: 897 Days
• Field of Search: 435/377, 435/383, 435/384, 435/363
• US Class Current: 435/377
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0657 Cardiomyocytes; Heart cells

Abstract

This invention provides a new procedure for generating cardiomyocyte lineage cells from embryonic stem cells for use in regenerative medicine. Differentiating by way of embryoid body formation or in serum is no longer required. Instead, the stem cells are plated onto a solid substrate, and differentiated in the presence of select factors and morphogens. After enrichment for cells with the appropriate phenotype, the cells are allowed to cluster into Cardiac Bodies™, which are remarkably homogeneous and suitable for the treatment of heart disease.

Claims

1. A method of differentiating a primate pluripotent stem (pPS) cell into a cell expressing α

-MHC comprising a) plating the undifferentiated pPS cell without forming an embryoid body directly onto a solid surface comprising a substrate;

b) contacting the pPS cell plated on the solid surface with one of the following;

     1) BMP;

or

     2) activin and BMP;

c) culturing the contacted pPS cell of b), thereby directing differentiation of the pPS cell into a cell expressing α

-MHC.

2. The method of claim 1, wherein the pPS cell is cultured serum-free in steps b) and c).

3. The method of claim 1, wherein the pPS cell is contacted with BMP.

4. The method of claim 1, wherein the pPS cell is contacted with activin and BMP.

5. The method of claim 1, wherein the substrate is produced by Engelbreth-Holm-Swarm tumor cells.

6. The method of claim 1, wherein the substrate is gelatin.

7. A method of differentiating a primate pluripotent stem (pPS) cell into a cell expressing Nkx2.5 comprising a) plating the undifferentiated pPS cell without forming an embryoid body directly onto a solid surface comprising a substrate;

b) contacting the pPS cell with activin and BMP;

c) culturing the contacted pPS cell of b), thereby directing differentiation of the pPS cell into a cell expressing Nkx2.5.

8. The method of claim 7, wherein the pPS cell is cultured serum-free in steps b) and c).

9. The method of claim 7, wherein the substrate is produced by Engelbreth-Holm-Swarm tumor cells.

10. The method of claim 7, wherein the substrate is gelatin.

11. A method of differentiating a primate pluripotent stem (pPS) cell into a cell expressing α

-sarcomeric actinin comprising a) plating the undifferentiated pPS cell without forming an embryoid body directly onto a solid surface comprising a substrate;

b) contacting the pPS cell with activin and BMP;

c) culturing the contacted pPS cell of b), thereby directing differentiation of the pPS cell into a cell expressing α

-sarcomeric actinin.

12. The method of claim 11, wherein the pPS cell is cultured serum-free in steps b) and c).

13. The method of claim 11, wherein the substrate is produced by Engelbreth-Holm-Swarm tumor cells.

14. The method of claim 11, wherein the substrate is gelatin.